Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Introduction to steroids in the menopause.

G Samsioe1

  • 1Department of Obstetrics and Gynecology, University of Göteborg, Sweden.

American Journal of Obstetrics and Gynecology
|June 1, 1992
PubMed
Summary

Estrogen therapy for menopausal symptoms can be safely combined with newer progestins, like norgestimate, to prevent endometrial hyperplasia without negatively impacting cardiovascular health.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increased blood cadmium levels were not associated with increased fracture risk but with increased total mortality in women: the Malmö Diet and Cancer Study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
Same author

Optimal tolerability of ultra-low-dose continuous combined 17beta-estradiol and norethisterone acetate: laboratory and safety results.

Climacteric : the journal of the International Menopause Society·2009
Same author

Sociodemographic risk factors of metabolic syndrome in middle-aged women: results from a population-based study of Swedish women, The Women's Health in the Lund Area (WHILA) Study.

Climacteric : the journal of the International Menopause Society·2008
Same author

Symptoms in peri- and postmenopausal women in relation to testosterone concentrations: data from The Women's Health in the Lund Area (WHILA) study.

Climacteric : the journal of the International Menopause Society·2008
Same author

Could androgens protect middle-aged women from cardiovascular events? A population-based study of Swedish women: The Women's Health in the Lund Area (WHILA) Study.

Climacteric : the journal of the International Menopause Society·2007
Same author

Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2007

Area of Science:

  • Reproductive Endocrinology
  • Cardiovascular Health
  • Oncology

Background:

  • Menopause, marked by declining ovarian function, leads to symptoms like hot flashes, vaginal atrophy, increased cardiovascular disease risk, and bone loss.
  • Estrogen therapy effectively alleviates menopausal symptoms but unopposed use significantly elevates the risk of endometrial hyperplasia and cancer.
  • The addition of progestin is necessary to counteract endometrial risks, yet certain progestins can negate estrogen's cardiovascular benefits and cause side effects.

Purpose of the Study:

  • To evaluate the safety and efficacy of newer progestins in combination with estrogen for menopausal symptom management.
  • To determine if modern progestins can prevent endometrial hyperplasia without compromising estrogen's positive cardiovascular effects.

Main Methods:

  • Review of clinical data and studies on hormone replacement therapy (HRT) regimens.
  • Analysis of the effects of different progestin types and doses on endometrial proliferation.
  • Assessment of the impact of combined estrogen-progestin therapy on cardiovascular markers.

Main Results:

  • Newer progestins, including norgestimate, gestodene, and desogestrel, effectively prevent endometrial hyperplasia when used with estrogen.
  • These newer progestins demonstrate a reduced tendency to reverse the beneficial cardiovascular effects associated with estrogen therapy.
  • Lower doses of these progestins maintain endometrial protection while minimizing adverse cardiovascular impacts.

Conclusions:

  • Combination therapy with estrogen and newer, lower-dose progestins offers a safer approach to managing menopausal symptoms.
  • This therapeutic strategy effectively addresses endometrial hyperplasia risks while preserving estrogen's cardiovascular advantages.
  • Modern progestins represent an improved option for hormone replacement therapy in postmenopausal women.

Related Experiment Videos